In the frame of a serial testing for RAS mutations in liquid biopsies in patients undergoing anti-EGFR therapy, a raise in CMF levels might represent a potential marker of cancer cell resistance onset and might anticipate the clinical evidence of disease progression and, thus, might allow a rational change in cancer therapy. This evidence concerns the gene EGFR and cancer.